Standout Papers

GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the Nati... 2014 2026 2018 2022 379
  1. GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration (2014)
    Andrew S. Levey, Lesley A. Inker et al. American Journal of Kidney Diseases
  2. Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency (2019)
    Andrew S. Levey, Ron T. Gansevoort et al. American Journal of Kidney Diseases

Immediate Impact

57 standout
Sub-graph 1 of 20

Citing Papers

Acute kidney injury
2025 Standout
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
2025 Standout
1 intermediate paper

Works of Kerry Willis being referenced

Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
2019 Standout
GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration
2014 Standout

Author Peers

Author Last Decade Papers Cites
Kerry Willis 467 26 17 235 201 13 847
Saori Oshiro 529 42 8 139 194 11 794
Jean-Marie Billiouw 330 18 20 115 167 16 717
Francesco Locatelli 421 17 5 221 140 5 818
Mary Rogerson 421 10 26 101 209 18 830
Nadia Stucchi 467 17 61 183 72 16 853
Christoph Wanner 324 91 38 150 146 19 867
Yunhua Liao 312 23 9 128 111 33 806
GJ Navis 286 50 7 201 431 22 907
Bijan Roshan 497 14 4 243 104 15 793
Haiyan Wang 538 31 15 109 167 28 869

All Works

Loading papers...

Rankless by CCL
2026